Cytoplasmic Accumulation of Heterogeneous Nuclear Ribonucleoprotein K Strongly Promotes Tumor Invasion in Renal Cell Carcinoma Cells

Matrix metalloproteinase 12 is induced by heterogeneous nuclear ribonucleoprotein K and promotes migration and invasion in nasopharyngeal carcinoma

(2014) I-Che Chung et al.   BMC CANCER

Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices

(2014) Eric Jonasch et al.   CURRENT MEDICAL RESEARCH AND OPINION

hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitors

(2013) Ziwei Xiao et al.   CARCINOGENESIS

Heterogeneous Nuclear Ribonucleoprotein K (hnRNP-K) Promotes Tumor Metastasis by Induction of Genes Involved in Extracellular Matrix, Cell Movement, and Angiogenesis

(2013) Ran Gao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors

(2012) Yanjie Zhang et al.   CELL CYCLE

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer

(2011) Feng Wang et al.   MEDICAL ONCOLOGY

Higher Expression of the Heterogeneous Nuclear Ribonucleoprotein K in Melanoma

(2010) Fushi Wen et al.   ANNALS OF SURGICAL ONCOLOGY

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

(2010) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer

(2009) P Barboro et al.   BRITISH JOURNAL OF CANCER

MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53

(2009) Martin Enge et al.   CANCER CELL

Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma

(2009) Ajay Matta et al.   INTERNATIONAL JOURNAL OF CANCER

Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53

(2009) Renyuan Zhou et al.   INTERNATIONAL JOURNAL OF CANCER

Renal cell carcinoma

(2009) Brian I Rini et al.   LANCET

Systematic identification of cell cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of composite motifs

(2009) S. Kosugi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Heterogeneous Ribonucleoprotein K and Thymidine Phosphorylase Are Independent Prognostic and Therapeutic Markers for Nasopharyngeal Carcinoma

(2008) L.-C. Chen et al.   CLINICAL CANCER RESEARCH

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE